These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25239826)

  • 1. In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor.
    Menhofer MH; Bartel D; Liebl J; Kubisch R; Busse J; Wagner E; Müller R; Vollmar AM; Zahler S
    Cardiovasc Res; 2014 Nov; 104(2):303-14. PubMed ID: 25239826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo.
    Kretzschmann VK; Gellrich D; Ullrich A; Zahler S; Vollmar AM; Kazmaier U; Fürst R
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):294-303. PubMed ID: 24285578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility.
    Menhofer MH; Kubisch R; Schreiner L; Zorn M; Foerster F; Mueller R; Raedler JO; Wagner E; Vollmar AM; Zahler S
    PLoS One; 2014; 9(11):e112542. PubMed ID: 25391145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
    Jiang WG; Ye L; Ji K; Frewer N; Ji J; Mason MD
    Int J Oncol; 2012 Nov; 41(5):1635-42. PubMed ID: 22971748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of novel integrin-targeting peptides on angiogenesis activity in HUVEC cells in vitro.
    Liu Y; Li Y; Xu Y
    Cell Biochem Funct; 2011 Jul; 29(5):429-35. PubMed ID: 21590697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
    Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
    Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ.
    Foerster F; Braig S; Moser C; Kubisch R; Busse J; Wagner E; Schmoeckel E; Mayr D; Schmitt S; Huettel S; Zischka H; Mueller R; Vollmar AM
    Cell Death Dis; 2014 Aug; 5(8):e1398. PubMed ID: 25165884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
    Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton.
    Bijman MN; van Nieuw Amerongen GP; Laurens N; van Hinsbergh VW; Boven E
    Mol Cancer Ther; 2006 Sep; 5(9):2348-57. PubMed ID: 16985069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion.
    Nguyen MP; Lee D; Lee SH; Lee HE; Lee HY; Lee YM
    Oncotarget; 2015 Jun; 6(18):16588-600. PubMed ID: 26078334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
    Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
    J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular disrupting activity of combretastatin analogues.
    Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
    Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
    Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
    J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activatio.
    Wang Y; Wang B; Guerram M; Sun L; Shi W; Tian C; Zhu X; Jiang Z; Zhang L
    Oncotarget; 2015 Oct; 6(30):29497-512. PubMed ID: 26470595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
    Ren X; Dai M; Lin LP; Li PK; Ding J
    Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.